NPCE vs. SRDX, ANIK, NVRO, SKIN, OSUR, PLSE, CVRX, TCMD, GUTS, and BVS
Should you be buying NeuroPace stock or one of its competitors? The main competitors of NeuroPace include Surmodics (SRDX), Anika Therapeutics (ANIK), Nevro (NVRO), Beauty Health (SKIN), OraSure Technologies (OSUR), Pulse Biosciences (PLSE), CVRx (CVRX), Tactile Systems Technology (TCMD), Fractyl Health (GUTS), and Bioventus (BVS). These companies are all part of the "surgical & medical instruments" industry.
Surmodics (NASDAQ:SRDX) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends.
In the previous week, NeuroPace had 6 more articles in the media than Surmodics. MarketBeat recorded 16 mentions for NeuroPace and 10 mentions for Surmodics. NeuroPace's average media sentiment score of 0.47 beat Surmodics' score of 0.31 indicating that Surmodics is being referred to more favorably in the media.
96.6% of Surmodics shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 8.9% of Surmodics shares are owned by company insiders. Comparatively, 27.5% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Surmodics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, NeuroPace has a beta of 2.06, indicating that its share price is 106% more volatile than the S&P 500.
Surmodics has a net margin of 9.44% compared to Surmodics' net margin of -50.38%. NeuroPace's return on equity of 13.30% beat Surmodics' return on equity.
Surmodics has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.
Surmodics currently has a consensus price target of $57.00, suggesting a potential upside of 75.17%. NeuroPace has a consensus price target of $15.67, suggesting a potential upside of 77.22%. Given Surmodics' higher probable upside, analysts plainly believe NeuroPace is more favorable than Surmodics.
Surmodics received 313 more outperform votes than NeuroPace when rated by MarketBeat users. Likewise, 67.13% of users gave Surmodics an outperform vote while only 55.81% of users gave NeuroPace an outperform vote.
Summary
Surmodics beats NeuroPace on 12 of the 18 factors compared between the two stocks.
Get NeuroPace News Delivered to You Automatically
Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NPCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroPace Competitors List
Related Companies and Tools
